Female libido med Addyi hits U.S. pharmacies; Sanofi launches PCSK9 med Praluent in U.K.;

> Sprout Pharmaceuticals rolled out the controversial female libido drug Addyi on Saturday, and analysts are saying that safety issues with the med could spur development of better follow-up drugs. Report

> Sanofi ($SNY) and Regeneron ($REGN) rolled out their cholesterol-fighting PCSK9 drug Praluent in the U.K., going up against Amgen's ($AMGN) Repatha, which launched there last month. Report

> Drugmakers prevailed in their latest fight against 340B hospital discounts on orphan drugs in nonorphan indications. Report

> Johnson & Johnson ($JNJ) won its first lawsuit over Tylenol and its potential links to liver damage; the company faces more than 200 similar claims of a design defects in the popular pain reliever. Report

And Finally... The Novartis ($NVS) cancer drug Tasigna delivered "meaningful clinical improvements" in 10 of 11 Parkinson's disease patients in an early-stage trial. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.